English

RLS GLOBAL AB (publ) YEAR-END REPORT, Q4, 2021

Report this content

OCTOBER 1st – DECEMBER 31st (previous year in brackets)

  • Net sales amounted to TSEK 219 (TSEK 139)
  • Earnings before interest and taxes (EBIT) amounted to TSEK -7 478 (TSEK -7 655)
  • Earning per share before dilution at SEK -0,11 (SEK -0,12)
  • Cash flow from operating activities amounted to TSEK -4 887 (TSEK -7 000)
  • Liquid assets at the end of the period TSEK 11 469 (TSEK 18 997)
  • Equity ratio was 75 % (87 %).

     

JANUARY 1st – DECEMBER 31st (previous year in brackets)

  • Net sales amounted to TSEK 653 (TSEK 2 043)                     
  • Earnings before interest and taxes (EBIT) amounted to TSEK -11 021 (TSEK -22 458)          
  • Earning per share before dilution at SEK -0,17 (SEK -0,34)                              
  • Cash flow from operating activities amounted to TSEK -8 353 (TSEK -22 219)                         
  • Liquid assets at the end of the period TSEK 11 469 (TSEK 18 997)
  • Equity ratio was 75 % (87 %).
     

SUMMARY OF EVENTS DURING FOURTH QUARTER

  • Activities in order to receive reimbursement in the European countries continue.
    The Netherlands are approved.                                                                                                                                                   
  • The collaboration with ConvaTec is progressing according to plan and several training sessions have been completed together with RLS.
  • The automatization project, aiming to lower the COGS of ChloraSolv and to secure
    a sustainable production is moving forward.
  • RLS has received the first order for ChloraSolv from ConvaTec.
  • RLS received a guaranteed bridgeloan from one of the main owners.


COVID-19

  • As throughout the year 2021, during the fourth quarter it has been challenging to arrange physical meetings with the healthcare sector. We look forward to meeting customers physically again.
     

TRADING PLACE AND CERTIFIED ADVISER
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012–2017, the company was listed on Aktietorget.

The Year-end Report Q4, 2021, is enclosed and is also available here:
https://rls.global/wp-content/uploads/2022/02/RLS_Global_Q4_2021_EN.pdf

PUBLICATION
This information was submitted for publication through the agency of the below contact person, at 09.00 CET on Feb 25th 2022.

CONTACT INFORMATION

Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

Subscribe

Documents & Links